Market Cap 582.38M
Revenue (ttm) 41.24M
Net Income (ttm) -400.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -971.56%
Debt to Equity Ratio 0.00
Volume 1,287,000
Avg Vol 1,520,970
Day's Range N/A - N/A
Shares Out 62.62M
Stochastic %K 96%
Beta 0.18
Analysts Sell
Price Target $8.47

Company Profile

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies;...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 299 8380
Fax: 617 299 8379
Address:
55 Cambridge Parkway, Cambridge, United States
StocktwitsNews
StocktwitsNews Jun. 23 at 2:54 AM
Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms $SAGE $SUPN $BIIB https://stocktwits.com/news/equity/markets/sage-therapeutics-stock-jp-morgan-sees-8-downside-after-supernus-buyout-terms/chmP8riRR55
0 · Reply
DonCorleone77
DonCorleone77 Jun. 22 at 8:25 PM
$SAGE Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan JPMorgan analyst Anupam Rama lowered the firm's price target on Sage Therapeutics to $8.50 from $11 and keeps a Neutral rating on the shares. The firm cites the acquisition deal price by Supernus Pharmaceuticals for the target cut.
0 · Reply
anachartanalyst
anachartanalyst Jun. 20 at 8:01 PM
$SAGE https://anachart.com/wp-content/uploads/ana_temp/1750449706_soc-img.jpg
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Jun. 19 at 8:13 PM
Halper Sadeh investigates $SAGE's $8.50+$3.50 CVR sale to Supernus. While the deal offers exit liquidity, Sage's fundamentals remain shaky: Q1 revenue still 84% below 2023 levels, burning $81.7M cash. Market pricing assumes flawless deal execution - law firm scrutiny suggests potential turbulence ahead. https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-verv-sage-ctlp-colb-on-behalf-of-shareholders-302486497.html
0 · Reply
Unicorn2020
Unicorn2020 Jun. 17 at 10:20 PM
$SUPN A major competitor of $VNDA just paid approximately $795 million to $SAGE, about $12/share for its new depression drug, Zurzuvae - the first and only oral treatment for postpartum depression. Note that SAGE has $6.77/share of cash-in-hand and $0 debt. The CEO of VANDA, Mihael H. Polymeropoulos wants a better offer than $12? That's not going to happen "IF" he keeps throwing the company cash away on silly ads and new employee hirings. Stop the frivolous spending, egg head!
1 · Reply
ZacksResearch
ZacksResearch Jun. 17 at 6:50 PM
$SAGE getting scooped up in $795 million deal — is this SUPN’s breakout moment? SUPN is acquiring Sage Therapeutics and locking down rights to depression drug Zurzuvae, signaling a bold push into neuroscience. Full deal breakdown here 👉 https://www.zacks.com/stock/news/2507455/sage-to-be-acquired-by-supernus-pharmaceuticals-in-795-million-deal?cid=sm-stocktwits-2-2507455-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2507455_TEASER
0 · Reply
ZacksResearch
ZacksResearch Jun. 17 at 5:47 PM
$SAGE surges 35.4% on acquisition news! 🚀 Supernus Pharmaceuticals is set to acquire Sage Therapeutics at $8.50/share, with a potential total value of $12/share if sales milestones are hit through a contingent value right. This acquisition will grant $SUPN rights to SAGE’s new depression drug, Zurzuvae, boosting its diverse neuroscience portfolio. Discover the full deal details here 👉 https://www.zacks.com/commentary/2507455/sage-to-be-acquired-by-supernus-pharmaceuticals-in-795-million-deal?cid=sm-stocktwits-2-2507455-body&ADID=SYND_STOCKTWITS_TWEET_2_2507455_BODY
0 · Reply
JarvisFlow
JarvisFlow Jun. 17 at 2:40 PM
Truist Securities updates rating for Sage Therapeutics ( $SAGE ) to Hold, target set at 8 → 9.
0 · Reply
JarvisFlow
JarvisFlow Jun. 17 at 2:18 PM
HC Wainwright & Co. has adjusted their stance on Sage Therapeutics ( $SAGE ), setting the rating to Neutral with a target price of 12.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jun. 17 at 2:17 PM
$SAGE HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $12 Price Target
0 · Reply
Latest News on SAGE
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

Jun 17, 2025, 8:31 AM EDT - 8 days ago

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

RGC VERV


Sage Therapeutics, Inc. (SAGE) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 10:33 PM EDT - 2 months ago

Sage Therapeutics, Inc. (SAGE) Q1 2025 Earnings Call Transcript


Sage Therapeutics Announces R&D Leadership Transition

Mar 4, 2025, 4:15 PM EST - 4 months ago

Sage Therapeutics Announces R&D Leadership Transition


Sage Therapeutics, Inc. (SAGE) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 9:29 PM EST - 4 months ago

Sage Therapeutics, Inc. (SAGE) Q4 2024 Earnings Call Transcript


Sage Therapeutics, Inc. (SAGE) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 9:35 PM EDT - 8 months ago

Sage Therapeutics, Inc. (SAGE) Q3 2024 Earnings Call Transcript


StocktwitsNews
StocktwitsNews Jun. 23 at 2:54 AM
Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms $SAGE $SUPN $BIIB https://stocktwits.com/news/equity/markets/sage-therapeutics-stock-jp-morgan-sees-8-downside-after-supernus-buyout-terms/chmP8riRR55
0 · Reply
DonCorleone77
DonCorleone77 Jun. 22 at 8:25 PM
$SAGE Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan JPMorgan analyst Anupam Rama lowered the firm's price target on Sage Therapeutics to $8.50 from $11 and keeps a Neutral rating on the shares. The firm cites the acquisition deal price by Supernus Pharmaceuticals for the target cut.
0 · Reply
anachartanalyst
anachartanalyst Jun. 20 at 8:01 PM
$SAGE https://anachart.com/wp-content/uploads/ana_temp/1750449706_soc-img.jpg
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Jun. 19 at 8:13 PM
Halper Sadeh investigates $SAGE's $8.50+$3.50 CVR sale to Supernus. While the deal offers exit liquidity, Sage's fundamentals remain shaky: Q1 revenue still 84% below 2023 levels, burning $81.7M cash. Market pricing assumes flawless deal execution - law firm scrutiny suggests potential turbulence ahead. https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-verv-sage-ctlp-colb-on-behalf-of-shareholders-302486497.html
0 · Reply
Unicorn2020
Unicorn2020 Jun. 17 at 10:20 PM
$SUPN A major competitor of $VNDA just paid approximately $795 million to $SAGE, about $12/share for its new depression drug, Zurzuvae - the first and only oral treatment for postpartum depression. Note that SAGE has $6.77/share of cash-in-hand and $0 debt. The CEO of VANDA, Mihael H. Polymeropoulos wants a better offer than $12? That's not going to happen "IF" he keeps throwing the company cash away on silly ads and new employee hirings. Stop the frivolous spending, egg head!
1 · Reply
ZacksResearch
ZacksResearch Jun. 17 at 6:50 PM
$SAGE getting scooped up in $795 million deal — is this SUPN’s breakout moment? SUPN is acquiring Sage Therapeutics and locking down rights to depression drug Zurzuvae, signaling a bold push into neuroscience. Full deal breakdown here 👉 https://www.zacks.com/stock/news/2507455/sage-to-be-acquired-by-supernus-pharmaceuticals-in-795-million-deal?cid=sm-stocktwits-2-2507455-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2507455_TEASER
0 · Reply
ZacksResearch
ZacksResearch Jun. 17 at 5:47 PM
$SAGE surges 35.4% on acquisition news! 🚀 Supernus Pharmaceuticals is set to acquire Sage Therapeutics at $8.50/share, with a potential total value of $12/share if sales milestones are hit through a contingent value right. This acquisition will grant $SUPN rights to SAGE’s new depression drug, Zurzuvae, boosting its diverse neuroscience portfolio. Discover the full deal details here 👉 https://www.zacks.com/commentary/2507455/sage-to-be-acquired-by-supernus-pharmaceuticals-in-795-million-deal?cid=sm-stocktwits-2-2507455-body&ADID=SYND_STOCKTWITS_TWEET_2_2507455_BODY
0 · Reply
JarvisFlow
JarvisFlow Jun. 17 at 2:40 PM
Truist Securities updates rating for Sage Therapeutics ( $SAGE ) to Hold, target set at 8 → 9.
0 · Reply
JarvisFlow
JarvisFlow Jun. 17 at 2:18 PM
HC Wainwright & Co. has adjusted their stance on Sage Therapeutics ( $SAGE ), setting the rating to Neutral with a target price of 12.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jun. 17 at 2:17 PM
$SAGE HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $12 Price Target
0 · Reply
JarvisFlow
JarvisFlow Jun. 17 at 12:30 PM
Canaccord Genuity has adjusted their stance on Sage Therapeutics ( $SAGE ), setting the rating to Hold with a target price of 8 → 8.5.
0 · Reply
Bombay55
Bombay55 Jun. 17 at 11:08 AM
$SRPT its interesting M&A activity in biotech recently $VERV $SAGE $CVAC
0 · Reply
dikbukiss
dikbukiss Jun. 17 at 12:18 AM
Today’s top 5 in my portfolio $SAGE $SMCL $AGEN $GBIO $JDST
1 · Reply
cubie
cubie Jun. 16 at 7:18 PM
$SRPT $SAGE $VKTX thanks for confirming how useless lemming analysts are. stonk goes up, they all raise price targets, stonk goes down, they all cut price targets lol. so fkng useless! and noobtards who think their any good are just next level dum dums. really!
0 · Reply
topstockalerts
topstockalerts Jun. 16 at 7:16 PM
$SAGE let's see some action in the power hour...🍾🍾
0 · Reply
cubie
cubie Jun. 16 at 7:13 PM
$SRPT holy cow 15000% for bears huh, if permabulls knew to buy poots from time to time 🤫😅🙄smh. its a spec bio that was in $100S just like $SAGE just like $VKT the lemming anaylsts had price targets in 100s then, what their price targets now?🤔😒 again lemmings are useless! Lesson for today for those who dont this basic already smh
0 · Reply
Steve_TheBull_Rogers
Steve_TheBull_Rogers Jun. 16 at 7:13 PM
$SAGE Called it back in January Congrats on the buy out longs who took the lows
0 · Reply
cubie
cubie Jun. 16 at 6:30 PM
$SAGE $VKTX tell me what price targets lemming analyst had for $SAGE wen that spec bio was in $90S? anyone who mentions lemmings as their reason to hold a stonk just confirm they are true noobs. thats all. useless as the lemming analysts themselves. cubie teaches
1 · Reply
benny2800
benny2800 Jun. 16 at 6:05 PM
$SAGE why doesnt this move
0 · Reply
topstockalerts
topstockalerts Jun. 16 at 5:53 PM
$SAGE strong watch at these levels👀...👀
0 · Reply
prismmarketview
prismmarketview Jun. 16 at 5:28 PM
$BATL, $SAGE, $HUSA, $TSSI, $GALT Geopolitical tensions and acquisition buzz are stirring up the markets today. Defense and biotech stocks are making bold moves as investors respond to global shifts and strategic deals. https://prismmarketview.com/prism-mid-day-movers-geopolitical-risk-and-aquisition-activity-drive-index-action/
0 · Reply
ChromeOnTheWheels
ChromeOnTheWheels Jun. 16 at 4:54 PM
$CPRX $ESPR $GERN $SAGE Glad I stayed long SAGE!
0 · Reply